Home About Us Pipeline News Investors Contacts Careers

Puma Biotechnology, Inc. Corporate Fact Sheet


RECENT NEWSEVENTSCLINICAL TRIALS



May 9, 2019 - Puma Biotechnology Reports First Quarter 2019 Financial Results
Read

May 8, 2019 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019
Read

April 25, 2019 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

April 9, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

April 4, 2019 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
Read

April 1, 2019 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
Read

March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019
Read

March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award
Read

March 18, 2019 - Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

March 5, 2019 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read

February 28, 2019 - Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
Read

February 15, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

February 13, 2019 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read

February 4, 2019 - Puma Biotechnology Announces Litigation Victory with Jury’s Decision
Read

January 11, 2019 - Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
Read

January 3, 2019 - Puma Biotechnology to Present at J. P. Morgan Healthcare Conference
Read

January 2, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

December 17, 2018 - Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
Read

December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

December 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 3, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read


May 15, 2019 - Bank of America Merrill Lynch 2019 Health Care Conference
More

May 9, 2019 - Puma Biotechnology 1Q-2019 Financial Results Conference Call
More

March 29 – April 3, 2019 - AACR Annual Meeting 2019
More

March 16-19, 2019 - Society of Gynecologic Oncology (SGO) 2019 Annual Meeting
More

March 12, 2019 - Cowen and Company 39th Annual Health Care Conference
More

February 28, 2019 - Puma Biotechnology 4Q-2018 Financial Results Conference Call
More

February 14, 2019 - Guggenheim Healthcare Talks Idea Forum, Oncology Day
More

January 9, 2019 - JP Morgan 37th Annual Healthcare Conference
More

December 17, 2018 - Puma Biotechnology NALA Trial Update Call
More

November 14, 2018 - Credit Suisse 27th Annual Healthcare Conference
More

November 1, 2018 - Puma Biotechnology 3Q-2018 Financial Results Conference Call
More

Puma-Sponsored Trials
Investigator-Sponsored Trials




Annual Report

2018 Annual Report

 Annual Report Archives

Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com